Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$422.72M
EBITDA Margin
-4.75%
TTM Avg
-133.22%
3Y Avg
-117.53%
5Y Avg
-82.53%
Market Cap
$424.10M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
Market Cap
$419.87M
EBITDA Margin
-1867.60%
TTM Avg
-990.65%
3Y Avg
-608.01%
5Y Avg
-2572.38%
Market Cap
$426.51M
EBITDA Margin
-211.30%
TTM Avg
-107.34%
3Y Avg
-56928.13%
5Y Avg
-38010.77%
Market Cap
$418.95M
EBITDA Margin
-232.13%
TTM Avg
-495.69%
3Y Avg
-578.57%
5Y Avg
-532.48%
Market Cap
$416.27M
EBITDA Margin
-189.54%
TTM Avg
-258.01%
3Y Avg
-315.18%
5Y Avg
-540.94%
Market Cap
$431.97M
EBITDA Margin
-14.39%
TTM Avg
-19.65%
3Y Avg
-40.36%
5Y Avg
-40.72%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | $422.86M | N/A | N/A | N/A | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | -4.75% | -133.22% | -117.53% | -82.53% |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | 0.24% | -1.36% | -6.49% | -5.53% |
| Prothena Corporation plc (PRTA)vs › | $419.87M | -1867.60% | -990.65% | -608.01% | -2572.38% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | -211.30% | -107.34% | -56928.13% | -38010.77% |
| Editas Medicine, Inc. (EDIT)vs › | $418.95M | -232.13% | -495.69% | -578.57% | -532.48% |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | -189.54% | -258.01% | -315.18% | -540.94% |
| Rezolute, Inc. (RZLT)vs › | $415.98M | N/A | N/A | N/A | N/A |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | -14.39% | -19.65% | -40.36% | -40.72% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
